{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:15:36Z","timestamp":1776071736180,"version":"3.50.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11060-026-05437-2","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:51:18Z","timestamp":1773215478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy approaches for the treatment of relapsed or progressive medulloblastoma"],"prefix":"10.1007","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4606-2269","authenticated-orcid":false,"given":"Mohammad H.","family":"Abu-Arja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-7495","authenticated-orcid":false,"given":"Austin","family":"Stuckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahawa T.","family":"Ghebrelul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murali","family":"Chintagumpala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7009-3466","authenticated-orcid":false,"given":"Michael D.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-8424","authenticated-orcid":false,"given":"Nabil","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"Supplement6","key":"5437_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M, Ballard C, Benedetti J, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS, Ostrom QT (2024) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2017\u20132021. Neurooncology 26(Supplement6):vi1\u2013vi85. https:\/\/doi.org\/10.1093\/neuonc\/noae145","journal-title":"Neurooncology"},{"issue":"6","key":"5437_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","volume":"31","author":"FMG Cavalli","year":"2017","unstructured":"Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Taylor MD (2017) Intertumoral heterogeneity within Medulloblastoma subgroups. Cancer Cell 31(6):737\u2013754e6. https:\/\/doi.org\/10.1016\/j.ccell.2017.05.005","journal-title":"Cancer Cell"},{"issue":"6","key":"5437_CR3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-016-1569-6","volume":"131","author":"V Ramaswamy","year":"2016","unstructured":"Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, Andr\u00e9 N, Massimino M, Pizer B, Pomeroy SL (2016) Risk stratification of childhood Medulloblastoma in the molecular era: the current consensus. Acta Neuropathol 131(6):821\u2013831. https:\/\/doi.org\/10.1007\/s00401-016-1569-6","journal-title":"Acta Neuropathol"},{"issue":"7","key":"5437_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JCO.20.01372","volume":"39","author":"A Gajjar","year":"2021","unstructured":"Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, Mahajan A, Su J, Bouffet E, Bartels U, Schechter T, Hassall T, Robertson T, Nicholls W, Gururangan S, Schroeder K, Sullivan M, Wheeler G, Hansford JR, Kellie SJ, Northcott PA (2021) Outcomes by clinical and molecular features in children with Medulloblastoma treated with Risk-Adapted therapy: results of an international phase III trial (SJMB03). J Clin Oncology: Official J Am Soc Clin Oncol 39(7):822\u2013835. https:\/\/doi.org\/10.1200\/JCO.20.01372","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"5437_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","volume":"5","author":"PA Northcott","year":"2019","unstructured":"Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, Rutkowski S, Ellison DW, Malkin D, Taylor MD, Gajjar A, Pfister SM (2019) Medulloblastoma Nat Reviews Disease Primers 5(1):11. https:\/\/doi.org\/10.1038\/s41572-019-0063-6","journal-title":"Medulloblastoma Nat Reviews Disease Primers"},{"issue":"2","key":"5437_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ijrobp.2005.07.962","volume":"64","author":"U Tabori","year":"2006","unstructured":"Tabori U, Sung L, Hukin J, Laperriere N, Crooks B, Carret AS, Silva M, Odame I, Mpofu C, Strother D, Wilson B, Samson Y, Bouffet E, Canadian Pediatric Brain Tumor Consortium (2006) Distinctive clinical course and pattern of relapse in adolescents with Medulloblastoma. Int J Radiat Oncol Biol Phys 64(2):402\u2013407. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.07.962","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"5437_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s43018-021-00319-0","volume":"3","author":"EI Hwang","year":"2022","unstructured":"Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, Pollack IF (2022) The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer 3(1):11\u201324. https:\/\/doi.org\/10.1038\/s43018-021-00319-0","journal-title":"Nat Cancer"},{"issue":"23","key":"5437_CR8","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","volume":"29","author":"A Das","year":"2023","unstructured":"Das A, Tabori U, Nahum S, Collins LC, Deyell NB, Dvir R, Faure-Conter R, Hassall C, Minturn TE, Edwards JE, Brookes M, Bianchi E, Levine V, Stone A, Sudhaman SC, Sanchez Ramirez S, Ercan S, Stengs AB, Chung L, Negm J, Morgenstern L, D. A (2023) Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch repair deficiency. Clin Cancer Research: Official J Am Association Cancer Res 29(23):4770\u20134783. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0411","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"1","key":"5437_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","volume":"28","author":"A Das","year":"2022","unstructured":"Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S, Ladany H, Chen D, Zatzman M, Cabric V, Nobre L, Bianchi V, Edwards M, Nahum S, Ercan LC, Nabbi AB, Tabori A, U (2022) Genomic predictors of response to PD-1 Inhibition in children with germline DNA replication repair deficiency. Nat Med 28(1):125\u2013135. https:\/\/doi.org\/10.1038\/s41591-021-01581-6","journal-title":"Nat Med"},{"issue":"23","key":"5437_CR10","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/JCO.23.02019","volume":"42","author":"FY Lin","year":"2024","unstructured":"Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Omer B (2024) Phase I trial of GD2.CART cells augmented with constitutive Interleukin-7 receptor for treatment of High-Grade pediatric CNS tumors. J Clin Oncology: Official J Am Soc Clin Oncol 42(23):2769\u20132779. https:\/\/doi.org\/10.1200\/JCO.23.02019","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"8046","key":"5437_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, Barsan V, Song KW, Kamens J, Baggott C, Kunicki M, Rietberg SP, Lim AS, Reschke A, Mavroukakis S, Egeler E, Moon J, Patel S, Chinnasamy H, Erickson C, Mackall C (2025) Intravenous and intracranial GD2-CAR T cells for H3K27M\u2009+\u2009diffuse midline gliomas. Nature 637(8046):708\u2013715. https:\/\/doi.org\/10.1038\/s41586-024-08171-9","journal-title":"Nature"},{"issue":"3","key":"5437_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, Rawlings-Rhea SD, Beam M, Steinmetzer L, Wilson AL, Brown C, Beebe A, Lindgren C, Gustafson JA, Wein A, Holtzclaw S, Hoeppner C, Goldstein HE, Browd SR, Hauptman JS, Lee A, Jensen MC (2025) Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic Pontine glioma: a phase 1 trial. Nat Med 31(3):861\u2013868. https:\/\/doi.org\/10.1038\/s41591-024-03451-3","journal-title":"Nat Med"},{"issue":"8","key":"5437_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neurooncology 23(8):1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neurooncology"},{"issue":"1","key":"5437_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41568-019-0223-8","volume":"20","author":"V Hovestadt","year":"2020","unstructured":"Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA (2020) Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat Rev Cancer 20(1):42\u201356. https:\/\/doi.org\/10.1038\/s41568-019-0223-8","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"5437_CR15","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu Y, Su Z, Tavana O, Gu W (2024) Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell 42(6):946\u2013967. https:\/\/doi.org\/10.1016\/j.ccell.2024.04.009","journal-title":"Cancer Cell"},{"issue":"7780","key":"5437_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-019-1650-0","volume":"574","author":"H Suzuki","year":"2019","unstructured":"Suzuki H, Kumar SA, Shuai S, Diaz-Navarro A, Gutierrez-Fernandez A, De Antonellis P, Cavalli FMG, Juraschka K, Farooq H, Shibahara I, Vladoiu MC, Zhang J, Abeysundara N, Przelicki D, Skowron P, Gauer N, Luu B, Daniels C, Wu X, Forget A, Taylor MD (2019) Recurrent noncoding U1 SnRNA mutations drive cryptic splicing in SHH Medulloblastoma. Nature 574(7780):707\u2013711. https:\/\/doi.org\/10.1038\/s41586-019-1650-0","journal-title":"Nature"},{"issue":"1","key":"5437_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","volume":"42","author":"Q Wu","year":"2021","unstructured":"Wu Q, Jiang L, Li SC, He QJ, Yang B, Cao J (2021) Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway. Acta Pharmacol Sin 42(1):1\u20139. https:\/\/doi.org\/10.1038\/s41401-020-0366-x","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"5437_CR18","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/neuonc\/noad031","volume":"25","author":"IJ Dunkel","year":"2023","unstructured":"Dunkel IJ, Doz F, Foreman NK, Hargrave D, Lassaletta A, Andr\u00e9 N, Hansford JR, Hassall T, Eyrich M, Gururangan S, Bartels U, Gajjar A, Howell L, Warad D, Pacius M, Tam R, Wang Y, Zhu L, Cohen K (2023) Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neurooncology 25(8):1530\u20131545. https:\/\/doi.org\/10.1093\/neuonc\/noad031","journal-title":"Neurooncology"},{"issue":"12","key":"5437_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S1470-2045(13)70449-2","volume":"14","author":"V Ramaswamy","year":"2013","unstructured":"Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Sch\u00fcller U, Gururangan S, McLendon R, Bigner D, Fouladi M, Ligon KL, Pomeroy SL, Dunn S, Triscott J, Jabado N, Taylor MD (2013) Recurrence patterns across Medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 14(12):1200\u20131207. https:\/\/doi.org\/10.1016\/S1470-2045(13)70449-2","journal-title":"Lancet Oncol"},{"issue":"Suppl 8","key":"5437_CR20","doi-asserted-by":"publisher","first-page":"viii154","DOI":"10.1093\/neuonc\/noae165.0607","volume":"26","author":"A Das","year":"2024","unstructured":"Das A, Fernandez N, Levine A, Smith K, Wang E, Galati M, Aamir Z, Chung J, Negm L, Friedman H, O\u2019Flaherty K, Crump O, Trinh Q, Nunes N, Bianchi V, Stengs L, Edwards M, Stein L, Bouffet E, Taylor M, Northcott P, Ramaswamy V, Hawkins C, Tabori U (2024) IMMU\u201314. Trans\u2013species analysis of replication\u2013repair deficient (RRD) Medulloblastoma and response to immune checkpoint inhibition: an IRRDC report. Neuro\u2013Oncology 26(Suppl 8):viii154\u2013viii155. https:\/\/doi.org\/10.1093\/neuonc\/noae165.0607","journal-title":"Neuro\u2013Oncology"},{"key":"5437_CR21","doi-asserted-by":"publisher","first-page":"1249929","DOI":"10.3389\/fphar.2023.1249929","volume":"14","author":"P Machy","year":"2023","unstructured":"Machy P, Mortier E, Birkl\u00e9 S (2023) Biology of GD2 ganglioside: implications for cancer immunotherapy. Front Pharmacol 14:1249929. https:\/\/doi.org\/10.3389\/fphar.2023.1249929","journal-title":"Front Pharmacol"},{"issue":"3","key":"5437_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41591-019-0383-9","volume":"25","author":"M Filbin","year":"2019","unstructured":"Filbin M, Monje M (2019) Developmental origins and emerging therapeutic opportunities for childhood cancer. Nat Med 25(3):367\u2013376. https:\/\/doi.org\/10.1038\/s41591-019-0383-9","journal-title":"Nat Med"},{"issue":"5","key":"5437_CR23","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/j.1471-4159.1991.tb02078.x","volume":"56","author":"L Svennerholm","year":"1991","unstructured":"Svennerholm L, Rynmark BM, Vilbergsson G, Fredman P, Gottfries J, M\u00e5nsson JE, Percy A (1991) Gangliosides in human fetal brain. J Neurochem 56(5):1763\u20131768. https:\/\/doi.org\/10.1111\/j.1471-4159.1991.tb02078.x","journal-title":"J Neurochem"},{"issue":"2","key":"5437_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0005-2760(94)90034-5","volume":"1214","author":"L Svennerholm","year":"1994","unstructured":"Svennerholm L, Bostr\u00f6m K, Fredman P, Jungbjer B, Lekman A, M\u00e5nsson JE, Rynmark BM (1994) Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1214(2):115\u2013123. https:\/\/doi.org\/10.1016\/0005-2760(94)90034-5","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"5437_CR25","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","volume":"30","author":"R Ciccone","year":"2024","unstructured":"Ciccone R, Quintarelli C, Camera A, Pezzella M, Caruso S, Manni S, Ottaviani A, Guercio M, Del Bufalo F, Quadraccia MC, Orlando D, Di Cecca S, Sinibaldi M, Aurigemma M, Iaffaldano L, Sarcinelli A, D\u2019Amore ML, Ceccarelli M, Nazio F, Marabitti V, Locatelli F (2024) GD2-Targeting CAR T-cell therapy for patients with GD2\u2009+\u2009Medulloblastoma. Clin Cancer Research: Official J Am Association Cancer Res 30(11):2545\u20132557. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1880","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"2","key":"5437_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/glycob\/9.2.101","volume":"9","author":"R Probstmeier","year":"1999","unstructured":"Probstmeier R, Pesheva P (1999) Tenascin-C inhibits beta1 integrin-dependent cell adhesion and neurite outgrowth on fibronectin by a disialoganglioside-mediated signaling mechanism. Glycobiology 9(2):101\u2013114. https:\/\/doi.org\/10.1093\/glycob\/9.2.101","journal-title":"Glycobiology"},{"issue":"3","key":"5437_CR27","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/ijms23031726","volume":"23","author":"HH Chuang","year":"2022","unstructured":"Chuang HH, Zhen YY, Tsai YC, Chuang CH, Hsiao M, Huang MS, Yang CJ (2022) FAK in cancer: from mechanisms to therapeutic strategies. Int J Mol Sci 23(3):1726. https:\/\/doi.org\/10.3390\/ijms23031726","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5437_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.18999\/nagjms.83.3.535","volume":"83","author":"P Zhang","year":"2021","unstructured":"Zhang P, Ohkawa Y, Yamamoto S, Momota H, Kato A, Kaneko K, Natsume A, Farhana Y, Ohmi Y, Okajima T, Bhuiyan RH, Wakabayashi T, Furukawa K, Furukawa K (2021) St8sia1-deficiency in mice alters tumor environments of gliomas, leading to reduced disease severity. Nagoya J Med Sci 83(3):535\u2013549. https:\/\/doi.org\/10.18999\/nagjms.83.3.535","journal-title":"Nagoya J Med Sci"},{"issue":"2","key":"5437_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","volume":"28","author":"J Theruvath","year":"2022","unstructured":"Theruvath J, Menard M, Smith BAH, Linde MH, Coles GL, Dalton GN, Wu W, Kiru L, Delaidelli A, Sotillo E, Silberstein JL, Geraghty AC, Banuelos A, Radosevich MT, Dhingra S, Heitzeneder S, Tousley A, Lattin J, Xu P, Huang J, Majzner RG (2022) Anti-GD2 synergizes with CD47 Blockade to mediate tumor eradication. Nat Med 28(2):333\u2013344. https:\/\/doi.org\/10.1038\/s41591-021-01625-x","journal-title":"Nat Med"},{"issue":"11","key":"5437_CR30","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R, Castillo P, Liu H, Brenner MK, Metelitsa LS, Gottschalk S, Rooney CM (2017) Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-Redirected T cells. Cancer Discov 7(11):1238\u20131247. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0538","journal-title":"Cancer Discov"},{"issue":"3","key":"5437_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L (2001) B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2(3):269\u2013274. https:\/\/doi.org\/10.1038\/85339","journal-title":"Nat Immunol"},{"issue":"4","key":"5437_CR32","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","volume":"172","author":"P Steinberger","year":"2004","unstructured":"Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, Zlabinger G, Pickl WF, St\u00f6ckl J, Knapp W (2004) Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol (Baltimore Md: 1950) 172(4):2352\u20132359. https:\/\/doi.org\/10.4049\/jimmunol.172.4.2352","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"5437_CR33","doi-asserted-by":"publisher","unstructured":"Prasad DV, Nguyen T, Li Z, Yang Y, Duong J, Wang Y, Dong C (2004) Murine B7-H3 is a negative regulator of T cells. J Immunol (Baltimore, Md.: 1950) 173(4):2500\u20132506. https:\/\/doi.org\/10.4049\/jimmunol.173.4.2500","DOI":"10.4049\/jimmunol.173.4.2500"},{"issue":"1","key":"5437_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3892\/or.2014.3587","volume":"33","author":"FB Kang","year":"2015","unstructured":"Kang FB, Wang L, Li D, Zhang YG, Sun DX (2015) Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression. Oncol Rep 33(1):274\u2013282. https:\/\/doi.org\/10.3892\/or.2014.3587","journal-title":"Oncol Rep"},{"key":"5437_CR35","doi-asserted-by":"publisher","unstructured":"Cardoso-Moreira M, Halbert J, Valloton D, Velten B, Chen C, Shao Y et al (2019) Gene expression across mammalian organ development. Nature 571(7766):505\u2013509. https:\/\/doi.org\/10.1038\/s41586-019-1338-5","DOI":"10.1038\/s41586-019-1338-5"},{"issue":"1","key":"5437_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13000-025-01645-y","volume":"20","author":"P Font\u00e3o","year":"2025","unstructured":"Font\u00e3o P, Teixeira GR, Moreno DA, Marques RF, Stavale JN, Malheiros SMF, J\u00fanior CA, Man\u00e7ano BM, Reis RM (2025) High B7-H3 protein expression in Medulloblastoma is associated with metastasis and unfavorable patient outcomes. Diagn Pathol 20(1):49. https:\/\/doi.org\/10.1186\/s13000-025-01645-y","journal-title":"Diagn Pathol"},{"key":"5437_CR37","doi-asserted-by":"publisher","unstructured":"Li S, Poolen GC, van Vliet LC, Schipper JG, Broekhuizen R, Monnikhof M et al (2022) Pediatric medulloblastoma express immune checkpoint B7-H3. Clin Transl Oncol 24(6):1204\u20131208. https:\/\/doi.org\/10.1007\/s12094-021-02762-y","DOI":"10.1007\/s12094-021-02762-y"},{"key":"5437_CR38","doi-asserted-by":"publisher","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al (2019) CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res 25(8):2560\u20132574. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432","DOI":"10.1158\/1078-0432.CCR-18-0432"},{"key":"5437_CR39","doi-asserted-by":"publisher","unstructured":"Nguyen P, Okeke E, Clay M, Haydar D, Justice J, O\u2019Reilly C et al (2020) Route of 41BB\/41BBL costimulation determines effector function of B7-H3-CAR.CD28\u03b6 T Cells. Mol Ther Oncolytics 18:202\u2013214. https:\/\/doi.org\/10.1016\/j.omto.2020.06.018","DOI":"10.1016\/j.omto.2020.06.018"},{"issue":"5","key":"5437_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/gb-2008-9-5-224","volume":"9","author":"J Filmus","year":"2008","unstructured":"Filmus J, Capurro M, Rast J (2008) Glypicans Genome Biology 9(5):224. https:\/\/doi.org\/10.1186\/gb-2008-9-5-224","journal-title":"Glypicans Genome Biology"},{"key":"5437_CR41","doi-asserted-by":"publisher","first-page":"857308","DOI":"10.3389\/fimmu.2022.857308","volume":"13","author":"G Chen","year":"2022","unstructured":"Chen G, Luo D, Zhong N, Li D, Zheng J, Liao H, Li Z, Lin X, Chen Q, Zhang C, Lu Y, Chan YT, Ren Q, Wang N, Feng Y (2022) GPC2 is a potential Diagnostic, Immunological, and prognostic biomarker in Pan-Cancer. Front Immunol 13:857308. https:\/\/doi.org\/10.3389\/fimmu.2022.857308","journal-title":"Front Immunol"},{"issue":"2","key":"5437_CR42","doi-asserted-by":"publisher","first-page":"e0279343","DOI":"10.1371\/journal.pone.0279343","volume":"18","author":"C Br\u00e9g\u00e8re","year":"2023","unstructured":"Br\u00e9g\u00e8re C, Fisch U, Halbeisen FS, Schneider C, Dittmar T, Stricker S, Aghlmandi S, Guzman R (2023) Doublecortin and Glypican-2 concentrations in the cerebrospinal fluid from infants are developmentally downregulated. PLoS ONE 18(2):e0279343. https:\/\/doi.org\/10.1371\/journal.pone.0279343","journal-title":"PLoS ONE"},{"issue":"9","key":"5437_CR43","doi-asserted-by":"publisher","first-page":"e004450","DOI":"10.1136\/jitc-2021-004450","volume":"10","author":"JB Foster","year":"2022","unstructured":"Foster JB, Griffin C, Rokita JL, Stern A, Brimley C, Rathi K, Lane MV, Buongervino SN, Smith T, Madsen PJ, Martinez D, Delaidelli A, Sorensen PH, Wechsler-Reya RJ, Karik\u00f3 K, Storm PB, Barrett DM, Resnick AC, Maris JM, Bosse KR (2022) Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. J Immunother Cancer 10(9):e004450. https:\/\/doi.org\/10.1136\/jitc-2021-004450","journal-title":"J Immunother Cancer"},{"issue":"12","key":"5437_CR44","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1089\/hum.2011.070","volume":"22","author":"DM Barrett","year":"2011","unstructured":"Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA (2011) Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 22(12):1575\u20131586. https:\/\/doi.org\/10.1089\/hum.2011.070","journal-title":"Hum Gene Ther"},{"issue":"12","key":"5437_CR45","doi-asserted-by":"publisher","first-page":"e962974","DOI":"10.4161\/21624011.2014.962974","volume":"3","author":"N Singh","year":"2015","unstructured":"Singh N, Barrett DM, Grupp SA (2015) Roadblocks to success for RNA cars in solid tumors. Oncoimmunology 3(12):e962974. https:\/\/doi.org\/10.4161\/21624011.2014.962974","journal-title":"Oncoimmunology"},{"issue":"14Suppl","key":"5437_CR46","doi-asserted-by":"publisher","first-page":"A09","DOI":"10.1158\/1538-7445.PEDCA19-A09","volume":"80","author":"S Heitzeneder","year":"2020","unstructured":"Heitzeneder S, Bosse KR, Zhu Z et al (2020) Abstract A09: Glypican-2 targeted CAR T cells designed to effectively eradicate endogenous site density solid tumors in the absence of toxicity. Cancer Res 80(14Suppl):A09. https:\/\/doi.org\/10.1158\/1538-7445.PEDCA19-A09","journal-title":"Cancer Res"},{"issue":"7","key":"5437_CR47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng X (2024) A comprehensive review of HER2 in cancer biology and therapeutics. Genes 15(7):903. https:\/\/doi.org\/10.3390\/genes15070903","journal-title":"Genes"},{"issue":"5","key":"5437_CR48","first-page":"2301","volume":"61","author":"DP Zelinski","year":"2001","unstructured":"Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61(5):2301\u20132306","journal-title":"Cancer Res"},{"key":"5437_CR49","doi-asserted-by":"publisher","first-page":"878365","DOI":"10.3389\/fimmu.2022.878365","volume":"13","author":"KM Knudson","year":"2022","unstructured":"Knudson KM, Hwang S, McCann MS, Joshi BH, Husain SR, Puri RK (2022) Recent advances in IL-13R\u03b12-Directed cancer immunotherapy. Front Immunol 13:878365. https:\/\/doi.org\/10.3389\/fimmu.2022.878365","journal-title":"Front Immunol"},{"issue":"3","key":"5437_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/mt.2012.210","volume":"21","author":"KK Chow","year":"2013","unstructured":"Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, Rainusso N, Wu MF, Liu H, Kew Y, Grossman RG, Powell S, Lee D, Ahmed N, Gottschalk S (2013) T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Therapy: J Am Soc Gene Therapy 21(3):629\u2013637. https:\/\/doi.org\/10.1038\/mt.2012.210","journal-title":"Mol Therapy: J Am Soc Gene Therapy"},{"key":"5437_CR51","doi-asserted-by":"publisher","unstructured":"Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL et al (2020) Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med 26(5):720\u2013731. https:\/\/doi.org\/10.1038\/s41591-020-0827-2","DOI":"10.1038\/s41591-020-0827-2"},{"issue":"4","key":"5437_CR52","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/neuonc\/nox182","volume":"20","author":"K Bielamowicz","year":"2018","unstructured":"Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, Wu MF, Orange JS, Sumazin P, Man TK, Joseph SK, Hegde M, Ahmed N (2018) Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neurooncology 20(4):506\u2013518. https:\/\/doi.org\/10.1093\/neuonc\/nox182","journal-title":"Neurooncology"},{"key":"5437_CR53","doi-asserted-by":"publisher","unstructured":"Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D et al (2024) Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med 30(4):1001\u20131012. https:\/\/doi.org\/10.1038\/s41591-024-02875-1","DOI":"10.1038\/s41591-024-02875-1"},{"issue":"12","key":"5437_CR54","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","volume":"67","author":"N Ahmed","year":"2007","unstructured":"Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, Bhattacharjee MB, Gilbertson RJ, Shine HD, Weiss HL, Rooney CM, Heslop HE, Gottschalk S (2007) Regression of experimental Medulloblastoma following transfer of HER2-specific T cells. Cancer Res 67(12):5957\u20135964. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4309","journal-title":"Cancer Res"},{"key":"5437_CR55","doi-asserted-by":"publisher","unstructured":"Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, K\u00fcnkele A et al (2021) Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat Med 27(9):1544\u20131552. https:\/\/doi.org\/10.1038\/s41591-021-01404-8","DOI":"10.1038\/s41591-021-01404-8"},{"key":"5437_CR56","doi-asserted-by":"publisher","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA et al (2021) Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest 131(13):e152477. https:\/\/doi.org\/10.1172\/JCI152477","DOI":"10.1172\/JCI152477"},{"key":"5437_CR57","doi-asserted-by":"publisher","unstructured":"Visvanathan A, Saulnier O, Chen C, Haldipur P, Orisme W, Delaidelli A et al (2024) Early rhombic lip Protogenin\u2009+\u2009ve stem cells in a human-specific neurovascular niche initiate and maintain group 3 medulloblastoma. Cell 187(17):4733\u20134750.e26. https:\/\/doi.org\/10.1016\/j.cell.2024.06.011","DOI":"10.1016\/j.cell.2024.06.011"},{"key":"5437_CR58","doi-asserted-by":"publisher","unstructured":"Hendrikse LD, Haldipur P, Saulnier O, Millman J, Sjoboen AH, Erickson AW et al (2022) Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature 609(7929):1021\u20131028. https:\/\/doi.org\/10.1038\/s41586-022-05215-w","DOI":"10.1038\/s41586-022-05215-w"},{"issue":"12","key":"5437_CR59","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1523\/JNEUROSCI.0473-10.2010","volume":"30","author":"YH Wong","year":"2010","unstructured":"Wong YH, Lu AC, Wang YC, Cheng HC, Chang C, Chen PH, Yu JY, Fann MJ (2010) Protogenin defines a transition stage during embryonic neurogenesis and prevents precocious neuronal differentiation. J Neuroscience: Official J Soc Neurosci 30(12):4428\u20134439. https:\/\/doi.org\/10.1523\/JNEUROSCI.0473-10.2010","journal-title":"J Neuroscience: Official J Soc Neurosci"},{"issue":"112","key":"5437_CR60","doi-asserted-by":"publisher","first-page":"eads0449","DOI":"10.1126\/sciimmunol.ads0449","volume":"10","author":"L Bunse","year":"2025","unstructured":"Bunse L, Bunse T, Kilian M, Quintana FJ, Platten M (2025) The immunology of brain tumors. Sci Immunol 10(112):eads0449. https:\/\/doi.org\/10.1126\/sciimmunol.ads0449","journal-title":"Sci Immunol"},{"key":"5437_CR61","doi-asserted-by":"publisher","unstructured":"Karimi E, Yu MW, Maritan SM, Perus LJM, Rezanejad M, Sorin M et al (2023) Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature 614(7948):555\u2013563. https:\/\/doi.org\/10.1038\/s41586-022-05680-3","DOI":"10.1038\/s41586-022-05680-3"},{"issue":"7","key":"5437_CR62","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","volume":"181","author":"E Friebel","year":"2020","unstructured":"Friebel E, Kapolou K, Unger S, N\u00fa\u00f1ez NG, Utz S, Rushing EJ, Regli L, Weller M, Greter M, Tugues S, Neidert MC, Becher B (2020) Single-Cell mapping of human brain cancer reveals Tumor-Specific instruction of Tissue-Invading leukocytes. Cell 181(7):1626\u20131642e20. https:\/\/doi.org\/10.1016\/j.cell.2020.04.055","journal-title":"Cell"},{"issue":"9","key":"5437_CR63","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1093\/brain\/awac222","volume":"145","author":"R Perelroizen","year":"2022","unstructured":"Perelroizen R, Philosof B, Budick-Harmelin N, Chernobylsky T, Ron A, Katzir R, Shimon D, Tessler A, Adir O, Gaoni-Yogev A, Meyer T, Krivitsky A, Shidlovsky N, Madi A, Ruppin E, Mayo L (2022) Astrocyte immunometabolic regulation of the tumour microenvironment drives glioblastoma pathogenicity. Brain 145(9):3288\u20133307. https:\/\/doi.org\/10.1093\/brain\/awac222","journal-title":"Brain"},{"key":"5437_CR64","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev-immunol-032713-120240","volume":"32","author":"D Nayak","year":"2014","unstructured":"Nayak D, Roth TL, McGavern DB (2014) Microglia development and function. Annu Rev Immunol 32:367\u2013402. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120240","journal-title":"Annu Rev Immunol"},{"key":"5437_CR65","doi-asserted-by":"publisher","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB et al (2025) Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637(8047):940\u2013946. https:\/\/doi.org\/10.1038\/s41586-024-08261-8","DOI":"10.1038\/s41586-024-08261-8"},{"key":"5437_CR66","doi-asserted-by":"publisher","unstructured":"Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH et al (2018). T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res 24(17):4175\u20134186. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1846","DOI":"10.1158\/1078-0432.CCR-17-1846"},{"issue":"3","key":"5437_CR67","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1215\/15228517-2006-006","volume":"8","author":"A El Andaloussi","year":"2006","unstructured":"El Andaloussi A, Lesniak MS (2006) An increase in CD4\u2009+\u2009CD25\u2009+\u2009FOXP3\u2009+\u2009regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neurooncology 8(3):234\u2013243. https:\/\/doi.org\/10.1215\/15228517-2006-006","journal-title":"Neurooncology"},{"key":"5437_CR68","doi-asserted-by":"publisher","unstructured":"Landi D, Navai SA, Brock RM, Fousek K, Nawas Z, Sanber K et al (2025) A checkpoint reversal receptor mediates bipartite activation and enhances CAR T-cell function. Cancer Res Commun 5(3):527\u2013548. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0125","DOI":"10.1158\/2767-9764.CRC-24-0125"},{"key":"5437_CR69","doi-asserted-by":"publisher","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","DOI":"10.1200\/JCO.21.01440"},{"issue":"1","key":"5437_CR70","doi-asserted-by":"publisher","first-page":"vdaf115","DOI":"10.1093\/noajnl\/vdaf115","volume":"7","author":"JTN Chan","year":"2025","unstructured":"Chan JTN, Henley-Waters J, Kayhanian S (2025) Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review. Neuro-oncology Adv 7(1):vdaf115. https:\/\/doi.org\/10.1093\/noajnl\/vdaf115","journal-title":"Neuro-oncology Adv"},{"issue":"2","key":"5437_CR71","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"5437_CR72","doi-asserted-by":"publisher","first-page":"e31557","DOI":"10.1002\/pbc.31557","volume":"72","author":"AB Ross","year":"2025","unstructured":"Ross AB, Puri K, Johnson TL, Correa LD, John TD, Friend B, Navai SA, Ahmed N, Hegde MG, Omer B, Heczey A, Salem BM, Tcharmtchi H, Rouce RH, Steffin DH, Krance RA, Rainusso NC, Bhar S (2025) Cardiovascular complications of immune effector cell therapies in pediatric hematological and solid tumors. Pediatr Blood Cancer 72(4):e31557. https:\/\/doi.org\/10.1002\/pbc.31557","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"5437_CR73","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood.2022017415","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL (2023) How I treat cytopenias after CAR T-cell therapy. Blood 141(20):2460\u20132469. https:\/\/doi.org\/10.1182\/blood.2022017415","journal-title":"Blood"},{"key":"5437_CR74","doi-asserted-by":"publisher","unstructured":"Mahdi J, Dietrich J, Straathof K, Roddie C, Scott BJ, Davidson TB et al (2023) Tumor inflammation-associated neurotoxicity. Nat Med 29(4):803\u2013810. https:\/\/doi.org\/10.1038\/s41591-023-02276-w","DOI":"10.1038\/s41591-023-02276-w"},{"key":"5437_CR75","doi-asserted-by":"publisher","unstructured":"Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M et al (2022) Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood 140(1):16\u201324. https:\/\/doi.org\/10.1182\/blood.2022015728","DOI":"10.1182\/blood.2022015728"},{"key":"5437_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-025-00586-x","author":"P Berg","year":"2025","unstructured":"Berg P, Bakker C, Sander M, Hasselblad Lundstr\u00f8m N, Erneholm K, Musuamba Tshinanu F, Kholmanshikh O, Van Nuffel F, M\u00fcller S, Ruppert-Seipp G, Maurer GD, Januskiene J, Mantziri M, Mulder B, van Nimwegen FA, Vasilcanu D, W\u00e4ndel Liminga U (2025) Secondary malignancy of T-cell origin after CAR T-cell therapy: ema\u2019s conclusions from the evaluation of 38 suspected cases. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-025-00586-xAdvance online publication","journal-title":"Gene Ther"},{"issue":"20","key":"5437_CR77","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA, Dos Santos C, D. M., Rejeski K (2024) Second primary malignancies after CAR T-Cell therapy: A systematic review and Meta-analysis of 5,517 lymphoma and myeloma patients. Clin Cancer Research: Official J Am Association Cancer Res 30(20):4690\u20134700. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1798","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"9","key":"5437_CR78","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1001\/jamaoncol.2021.2224","volume":"7","author":"SES Leary","year":"2021","unstructured":"Leary SES, Packer RJ, Li Y, Billups CA, Smith KS, Jaju A, Heier L, Burger P, Walsh K, Han Y, Embry L, Hadley J, Kumar R, Michalski J, Hwang E, Gajjar A, Pollack IF, Fouladi M, Northcott PA, Olson JM (2021) Efficacy of carboplatin and isotretinoin in children with High-risk medulloblastoma: A randomized clinical trial from the children\u2019s oncology group. JAMA Oncol 7(9):1313\u20131321. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2224","journal-title":"JAMA Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05437-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05437-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05437-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:37:23Z","timestamp":1776069443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05437-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["5437"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05437-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review and does not involve any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Mohammad H. Abu-Arja receives salary support from the following:- The Rally Young Investigator and Kids Join The Fight Young Investigator Grant. Grant No.: 25YIN38. -\tThe Be Brooks Brave Fund St. Baldrick\u2019s Foundation Fellowship Award. Grant No.: 1-1186766. - The National Cancer Institute (NCI) Paul Calabresi Career Development Award for Clinical Oncology (K12). Grant ID: 5K12CA090433-23Nabil Ahmed is named inventor on patent applications in the field of CAR T cell therapy owned by Baylor College of Medicine. He also received one-time royalties from Celgene and Cell Medica, consulted in the past for Adaptimmune, and continues to consult for Equillium (pro bono) and The Children\u2019s Cancer Hospital, Egypt 57357. None of these relationships conflicts with the published work.All other authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}